IL-12 adoptive T cell therapy (RheoSwitch) (Intrexon/NCI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-12 adoptive T cell therapy (RheoSwitch) (Intrexon/NCI)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Peripheral blood stem cell therapy
Mechanisms of ActionInterleukin-12 modulators
TargetsInterleukin-12
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPrecigen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstitutePrecigen Inc
Active IndicationsN/A
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A